REGENXBIO (RGNX) Stock Forecast & Price Target

Regenxbio is supported by a compelling late-stage gene-therapy pipeline with multiple catalysts, led by RGX-202, whose BLA submission is set to begin in 3Q26 and could support accelerated approval in 2H27 after strong pivotal signals, including >93% microdystrophin expression and functional improvement. The company’s regulatory progress on RGX-121, where FDA has accepted existing data for accelerated approval consideration without additional patients or studies, reinforces the platform’s potential to advance rare-disease assets efficiently while reducing development risk. Financially, 2Q26 revenue reached $108.0M, net income was $22.7M, and pro forma cash rose to about $313M, extending runway into 4Q27 and providing flexibility to fund upcoming wet AMD, NPDR, and DMD milestones.

Regenxbio is facing a material setback as the FDA clinical hold on RGX-121, triggered by asymptomatic spine MRI findings in five CAMPSIITE participants, delays the BLA resubmission and forces longer-term follow-up before the benefit-risk profile can be assessed. Although the findings are currently viewed as nonserious and possibly benign, the lack of clinical or pathological confirmation, combined with the unknown prevalence and significance of these abnormalities in this patient population, raises meaningful regulatory and development risk for the company’s CNS franchise. Removing RGX-121 from the model underscores the weakened near-term value proposition, leaving the company more dependent on other pipeline assets while increasing execution uncertainty across a clinical-stage gene therapy platform.